Literature DB >> 15284486

Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1.

Gadi Borkow1, Humberto Herman Lara, Mila Ayash-Rashkovsky, Einat Tavor, Aviva Lapidot, Zvi Bentwich, Alik Honigman.   

Abstract

We report a fast, highly sensitive method for detecting and testing drug resistance of M-tropic and T-tropic laboratory and primary HIV-1 isolates. cMAGI cells are infected with an adenovirus vector harboring the luciferase reporter gene controlled by HIV-1 Tat-responsive element, TAR. HIV-1 Tat production by HIV-1 chronically infected cells, or by cMAGI cells as early as two days after being acutely infected with HIV-1, is readily monitored in the presence or absence of antiviral drugs. This method is more sensitive than HIV-1 Tat dependant production of beta-galactosidase in the cMAGI cells. The fast answer, ease and sensitivity as well as the possibility of using this method in high throughput screening, makes it an very attractive tool for phenotypic detection of HIV-1 in clinical samples as well as a sensitive assay for monitoring drug resistant HIV-1 variants. This method can also be used for discovery of novel anti HIV-1 drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284486     DOI: 10.1023/B:VIRU.0000036386.47149.62

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  27 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

Authors:  Ariela Zussman; Liliana Lara; Humberto H Lara; Zvi Bentwich; Gadi Borkow
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

3.  The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.

Authors:  J Barnard; G Borkow; M A Parniak
Journal:  Biochemistry       Date:  1997-06-24       Impact factor: 3.162

4.  Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.

Authors:  M A Wainberg; M Hsu; Z Gu; G Borkow; M A Parniak
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

5.  Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.

Authors:  A Litovchick; A Lapidot; M Eisenstein; A Kalinkovich; G Borkow
Journal:  Biochemistry       Date:  2001-12-25       Impact factor: 3.162

6.  A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors.

Authors:  J H Axelrod; A Honigman
Journal:  AIDS Res Hum Retroviruses       Date:  1999-05-20       Impact factor: 2.205

7.  Activation of the human immunodeficiency virus long terminal repeat in THP-1 cells by a staphylococcal extracellular product.

Authors:  S J Klebanoff; F Kazazi; W C Van Voorhis; K G Schlechte
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

Review 8.  Antiretroviral resistance testing for clinical management.

Authors:  Bryan E Youree; Richard T D'Aquila
Journal:  AIDS Rev       Date:  2002 Jan-Mar       Impact factor: 2.500

9.  Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.

Authors:  M Pirounaki; N A Heyden; M Arens; L Ratner
Journal:  J Virol Methods       Date:  2000-03       Impact factor: 2.014

10.  A bioluminescence assay for gene expression by continuously growing mammalian cells: application for detection of human immunodeficiency virus type 1 (HIV-1).

Authors:  S Israel; A Honigman
Journal:  Gene       Date:  1991-08-15       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.